Press release
Uveitis Market Size in the 7MM was over ~USD 1,100 million in 2021
The Uveitis market report provides current treatment practices, Uveitis emerging drugs, Uveitis market share of the individual therapies, current and forecasted Uveitis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Uveitis treatment practice/algorithm, Uveitis market drivers, Uveitis market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Uveitis market.
Key takeaways from the Uveitis Market Report
• As per DelveInsight, the total Uveitis prevalent cases in the 7MM were observed to be about 916,000 in 2021.
• According to DelveInsight, the majority of cases of uveitis are female as compared to male. There were total close to 168,500 female and nearly 163,800 male cases of uveitis in 2021, in the United States.
• The leading Uveitis Market Companies includes Sirion Therapeutics, Santen, Tarsier Pharma, Acelyrin Inc, and others.
• Promising Uveitis Pipeline Therapies includes Izokibep, TRS01, Sirolimus, Durezol, and others.
Discover which therapies are expected to grab the major Uveitis market share, click here for Uveitis Market Research Report @ https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Uveitis Overview
Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveal tract.
Uveitis Epidemiology Segmentation in the 7MM
• Total Uveitis Prevalent Cases
• Uveitis Age-specific Diagnosed Prevalent Cases
• Uveitis Diagnosed Prevalence of Non-infectious by Anatomical Location
• Uveitis Gender-specific Diagnosed Prevalent Cases
• Uveitis Type-specific Diagnosed Prevalent Cases
• Uveitis Gender-specific Diagnosed Prevalence of Anterior Non-infectious
Download the report to understand which factors are driving Uveitis market trends, click here for Uveitis Market Forecast @ https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Latest Breakthroughs or News of the Uveitis Treatment Landscape
• In October 2021, Bausch + Lomb and Clearside Biomedical announced that the United States Food and Drug Administration approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis.
• Recently in March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
• In October 2021, the United States Food and Drug Administration approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis
Uveitis Market Insights
Uveitis is an inflammatory condition associated with visual impairment, blindness, and reduced quality of life. The condition often affects patients in their most active and economically productive years. Uveitis has been demonstrated to cause less than 50% of cases of legal blindness in the United States and the European Union and up to 25% of cases of legal blindness in developing countries. Several drugs are available for the management of noninfectious uveitis including corticosteroids, immunosuppressive agents, and more recently biologics.
Uveitis Market Size
The Uveitis market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a significant rate during the forecasted period.
Learn more about the Uveitis FDA-approved drugs, click here for Uveitis Emerging Drugs & Companies and Uveitis Treatment Market @ https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Uveitis Market Research Report
• Coverage- 7MM
• Uveitis Companies- Sirion Therapeutics, Santen, Tarsier Pharma, Acelyrin Inc, and others.
• Uveitis Pipeline Therapies- Izokibep, TRS01, Sirolimus, Durezol, and others.
• Uveitis Market Dynamics: Uveitis Market Drivers and Barriers
• Uveitis Market Access and Reimbursement
To discover more about Uveitis Market Drugs in development, click here for Uveitis Market Dynamics and Uveitis Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Executive Summary of Uveitis
3. Competitive Intelligence Analysis for Uveitis
4. Uveitis: Market Overview at a Glance
5. Uveitis: Disease Background and Overview
6. Patient Journey
7. Uveitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Uveitis Unmet Needs
10. Key Endpoints of Uveitis Treatment
11. Uveitis Marketed Products
12. Uveitis Emerging Therapies
13. Uveitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Uveitis Market Outlook
16. Access and Reimbursement Overview of Uveitis
17. KOL Views
18. Uveitis Market Drivers
19. Uveitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
To read more about the Uveitis Patient Population of the report, click here for Uveitis Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Market Size in the 7MM was over ~USD 1,100 million in 2021 here
News-ID: 2920364 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Uveitis
Uveitis Market : An Overview Report
Introduction:
Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye. It can lead to vision impairment or even blindness if left untreated. Uveitis is categorized into different types, including anterior, intermediate, posterior, and panuveitis, depending on the part of the eye affected. The condition can be caused by infections, autoimmune diseases, or trauma. With increasing cases of autoimmune disorders and infectious diseases, the prevalence of uveitis…
Uveitis Treatment Market Size, Share | Trend 2030
Exclusive Report by Ameco Research: Uveitis Treatment Market Size Projected to Reach USD 2 Billion by 2030, Growing at 6% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Uveitis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality market research…
Uveitis - Drug Pipeline Landscape, 2022
New York, Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of…
Uveitis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based…
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
